19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      LncRNA MALAT1 Promotes Survival of Epithelial Ovarian Cancer Cells by Downregulating miR-145-5p

      research-article
      1 , 2 , 3
      Cancer Management and Research
      Dove
      MALAT1, EOC, miR-145-5p, cell survival

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          This paper was aimed at investigating the regulatory mechanism of long non-coding RNA metastasis-associated lung adenocarcinoma transcript-1 (MALAT1) in epithelial ovarian cancer (EOC).

          Materials and Methods

          MALAT1 and miR-145-5p expression in the tissues, serum, and EOC cell lines (TOV-112D, TOV-21G) of patients with EOC were detected. The two genes were transfected into the cells via upregulating or downregulating their expression. Levels of apoptosis-related proteins (Caspase-3, Bax, Bcl-2) were analyzed. Mechanisms of cell proliferation, invasion, and apoptosis were studied.

          Results

          MALAT1 was high expressed in EOC tissues, while miR-145-5p was poorly expressed in them. The areas under the curves (AUCs) of the two genes for diagnosing EOC were greater than 0.850, and the two had a significantly negative correlation. According to multivariate Cox regression analysis, high MALAT1 expression, tumor size, degree of differentiation, case staging, and lymph node metastasis were the independent risk factors affecting prognosis. The 5-year overall survival rate (OSR) of patients with low MALAT1 expression was remarkably higher than that of those with high expression. Overexpressing miR-145-5p and silencing MALAT1 could inhibit EOC cells from proliferating and invading, increase their apoptotic rate, and improve levels of the apoptosis-related proteins. After co-transfection with MALAT1-inhibitor + miR-145-5p-inhibitor, the proliferation and invasion of TOV-112D and TOV-21G cells were inhibited and the apoptotic rate rose more obviously. Inhibiting MALAT1 could increase miR-145-5p expression, thus inhibiting EOC cells from proliferating and invading and thereby increasing their apoptotic rate.

          Conclusion

          MALAT1 promotes EOC cells’ survival by downregulating miR-145-5p so it may become a new direction for EOC diagnosis and gene therapy.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Long Noncoding RNAs in Cancer Pathways.

          Genome-wide cancer mutation analyses are revealing an extensive landscape of functional mutations within the noncoding genome, with profound effects on the expression of long noncoding RNAs (lncRNAs). While the exquisite regulation of lncRNA transcription can provide signals of malignant transformation, we now understand that lncRNAs drive many important cancer phenotypes through their interactions with other cellular macromolecules including DNA, protein, and RNA. Recent advancements in surveying lncRNA molecular mechanisms are now providing the tools to functionally annotate these cancer-associated transcripts, making these molecules attractive targets for therapeutic intervention in the fight against cancer.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Epithelial ovarian cancer

            Epithelial ovarian cancer generally presents at an advanced stage and is the most common cause of gynaecological cancer death. Treatment requires expert multidisciplinary care. Population-based screening has been ineffective, but new approaches for early diagnosis and prevention that leverage molecular genomics are in development. Initial therapy includes surgery and adjuvant therapy. Epithelial ovarian cancer is composed of distinct histological subtypes with unique genomic characteristics, which are improving the precision and effectiveness of therapy, allowing discovery of predictors of response such as mutations in breast cancer susceptibility genes BRCA1 and BRCA2, and homologous recombination deficiency for DNA damage response pathway inhibitors or resistance (cyclin E1). Rapidly evolving techniques to measure genomic changes in tumour and blood allow for assessment of sensitivity and emergence of resistance to therapy, and might be accurate indicators of residual disease. Recurrence is usually incurable, and patient symptom control and quality of life are key considerations at this stage. Treatments for recurrence have to be designed from a patient's perspective and incorporate meaningful measures of benefit. Urgent progress is needed to develop evidence and consensus-based treatment guidelines for each subgroup, and requires close international cooperation in conducting clinical trials through academic research groups such as the Gynecologic Cancer Intergroup.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss

              In this study, Arun et al. show that loss of Malat1 lncRNA in a mouse model of luminal B breast cancer (MMTV-PyMT) results in a marked reduction in tumor cell proliferation, induces the differentiation of primary mammary tumors from highly undifferentiated carcinomas to cystic tumors, and reduces tumor metastasis. The findings demonstrate for the first time a functional role of Malat1 in regulating critical processes in mammary cancer pathogenesis.
                Bookmark

                Author and article information

                Journal
                Cancer Manag Res
                Cancer Manag Res
                cmar
                cancmanres
                Cancer Management and Research
                Dove
                1179-1322
                06 November 2020
                2020
                : 12
                : 11359-11369
                Affiliations
                [1 ]Department of Gynaecology and Obstetrics, China-Japan Union Hospital of Jilin University , Changchun 130000, Jilin, People’s Republic of China
                [2 ]Department of Dermatology, China-Japan Union Hospital of Jilin University , Changchun, Jilin, 130000, People’s Republic of China
                [3 ]Central Research Room, China-Japan Union Hospital of Jilin University , Changchun 130000, Jilin, People’s Republic of China
                Author notes
                Correspondence: Yi-Min WangCentral Research Room, China-Japan Union Hospital of Jilin University , No. 126 Sendai Street, Nanguan District, Changchun130000, Jilin, People’s Republic of ChinaTel +86-13265896584 Email Yiminwang@jlu.edu.cn
                Ye ZhaoDepartment of Dermatological, China-Japan Union Hospital of Jilin University , No. 126 Sendai Street, Nanguan District, Changchun130000, Jilin, People’s Republic of ChinaTel +86-13569874521 Email yezhao45@outlook.com
                [*]

                These authors contributed equally to this work

                Article
                267355
                10.2147/CMAR.S267355
                7654532
                33192095
                f757e3db-0b36-4218-92e7-20441f73ea20
                © 2020 Wang et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 11 June 2020
                : 06 September 2020
                Page count
                Figures: 7, Tables: 3, References: 27, Pages: 11
                Categories
                Original Research

                Oncology & Radiotherapy
                malat1,eoc,mir-145-5p,cell survival
                Oncology & Radiotherapy
                malat1, eoc, mir-145-5p, cell survival

                Comments

                Comment on this article